In this review, we use model of care (MoC) to signify a setting-specific framework that outlines how to provide PWID with relevant services and interventions throughout the HCV cascade of care. Four key questions are critical to simplify models of care for treating hepatitis C in people who use drugs
Models of care for HCV in PWID need to be redesigned to reflect the recent availability of direct-acting antiviral agents (DAAs) if countries are to meet their commitments to eliminating HCV as a public health threat by 2030. 

This review has been prepared within the framework of the Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT).